GSH與pH雙響應型載藥ZIF
首發時間:2023-04-25
摘要:(1)探究負載抗癌藥物DOX的納米粒HSZ@DOX的雙響應性以及靶向性,并對其體外抗腫瘤活性進行研究。將HSZ@DOX于不同pH的緩沖溶液中以及伴有GSH存在的不同pH緩沖溶液進行藥物釋放實驗,探究其pH、GSH雙響應特性。選取HepG2肝癌細胞和HEK-293t正常組織細胞驗證其細胞毒性及靶向性。HSZ@DOX的體外藥物釋放量在pH為5.6、GSH存在的條件下,藥物釋放量為93.93%,遠高于中性環境、沒有GSH存在時的釋放量(17.81%)。在細胞實驗中的結果表明:空白載體HSZ有良好的生物相容性。載藥納米粒HSZ@DOX對于腫瘤細胞和正常組織細胞有較高的選擇靶向性。
For information in English, please click here
GSH and pH dual-responsive drug carrier ZIF
Abstract:To explore the biresponsiveness and targeting of nanoparticle HSZ@DOX loaded with anticancer drug DOX, and to study its antitumor activity in vitro. The drug release experiments were carried out in buffer solutions HSZ@DOX different pH and different pH buffer solutions with GSH to explore the dual response characteristics of pH and GSH. HepG2 hepatoma cells and HEK-293t normal histiocytes were selected to verify their cytotoxicity and targeting. The drug release amount in vitro of HSZ@DOX was 93.93% under the condition of pH 5.6 and the presence of GSH, which was much higher than that released in neutral environment and without GSH (17.81%). The results in cell experiments showed that the blank carrier HSZ had good biocompatibility. Drug-loaded nanoparticles HSZ@DOX have high selective targeting for tumor cells and normal tissue cells.
Keywords: Pharmacy Tumor pH; GSH; ZIF-90; Dual response
基金:
引用
No.****
動態公開評議
共計0人參與
勘誤表
GSH與pH雙響應型載藥ZIF
評論
全部評論